Impact Biomedical (IBO) Total Non-Current Liabilities (2022 - 2023)
Impact Biomedical's (IBO) quarterly Total Non-Current Liabilities came in at $15.5 million in Q3 2023, up 12.1% on a QoQ basis from $13.8 million in Q4 2022.
Impact Biomedical (IBO) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Impact Biomedical (IBO) has 2 years of Total Non-Current Liabilities data on file, last reported at $15.5 million in Q3 2023.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $15.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $15.5 million (changed N/A YoY) and the FY2022 annual result came in at $13.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $15.5 million in Q3 2023, from $13.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $15.5 million in Q3 2023 to a low of $13.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 15.50 Mn |
| Dec 31, 2022 | 13.83 Mn |